ASSEMBLY BIOSCIENCES, INC. (ASMB) Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Assembly Biosciences, Inc. NASDAQ:ASMB Healthcare · Biotechnology
Mkt Cap $409.86M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 3
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
Assembly Biosciences dosed the first two participants in a Phase 2 study of ABI-6250, its investigational oral NTCP inhibitor for chronic hepatitis delta virus infection.
The multicenter, open-label study (NCT07762027) will enroll approximately 80 participants across two once-daily oral dose levels, evaluating safety, PK, and antiviral activity, with initial data expected in the fourth quarter of 2027.
Under Assembly Bio's 12-year collaboration with Gilead Sciences, Gilead can license ABI-6250 through Phase 2 completion for a $90 million opt-in fee, providing a clear strategic and financial path for the asset.
The program follows encouraging Phase 1a results, including a ~4-day half-life supporting once-daily dosing and an oral alternative to the only approved HDV therapy, which requires daily injections.
• 3d ago AI analysis › Press Release
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
Assembly Biosciences will present new Phase 1a data for its oral NTCP inhibitor ABI-6250 at AASLD's The Liver Meeting 2026, November 5-9 in Denver, with one poster named a Poster of Distinction.
In the randomized, blinded Phase 1a study, ABI-6250 was well tolerated with no serious adverse events and showed dose-dependent, reversible bile acid increases consistent with NTCP target engagement.
The company plans to initiate Phase 2 studies in chronic HDV infection in Q4 2026 and in cholestatic liver diseases (PBC and PSC) in Q1 2027.
• 27d ago AI analysis › Press Release
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
Assembly Biosciences announced that senior management will present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. ET on September 16, 2026.
A live webcast and replay will be available on the Events and Presentations section of the company's investor relations website.
The release contains no new clinical, regulatory, or financial data; the forward-looking statements section only restates existing risks, including those tied to the company's collaboration with Gilead.
• 1mo ago AI analysis › Press Release ● Major
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
Assembly Biosciences exercised its option to share 40% of U.S. development costs and profits for its HSV helicase-primase inhibitor program with Gilead.
The move expands Assembly Bio's potential upside to up to $330 million in regulatory and commercial milestones and tiered royalties, while Gilead retains sole responsibility for clinical development and commercialization.
The company also confirmed a $75 million option continuation payment due in Q4 2026 and expects its cash runway to extend into 2029.
• 1mo ago AI analysis › Press Release
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Assembly Biosciences reported Q2 revenue of $13.4 million, up from $9.6 million in the prior year, while net loss narrowed to $3.9 million or $0.20 per share.
The company strengthened its balance sheet with a $115 million financing, ending the quarter with $320.4 million in cash, which projects a runway into 2029 inclusive of a $75 million payment from Gilead expected in Q4.
Pipeline updates include the expansion of ABI-6250 into cholestatic liver diseases and the selection of GS-1179 for Phase 2 trials in recurrent genital herpes expected to begin by year-end 2026.
• 2mo ago AI analysis › Press Release
Assembly Biosciences Announces Upcoming Investor Conference Presentations
Assembly Biosciences announced that senior management will participate in fireside chats at two upcoming investor conferences.
The company will present at the Jefferies 2026 Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8.
Webcast replays will be available on the company’s investor relations website following each event.
• 5mo ago AI analysis › Press Release
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Assembly Biosciences closed a registered offering of 3.92 million shares of common stock at $26.50 per share, including the full exercise of the underwriters' option for 566,040 additional shares.
The company also sold 415,000 pre-funded warrants to an existing investor at $26.499 each, generating aggregate gross proceeds of approximately $115 million.
Net proceeds will be used to fund clinical development of pipeline candidates targeting viral and liver diseases, as well as for general corporate purposes.
• 5mo ago AI analysis › Press Release ● Major ⚠ 2
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
Assembly Biosciences priced a $100 million registered offering of common stock and pre-funded warrants at $26.50 per share.
The deal includes 3.36 million shares of common stock and 415,000 pre-funded warrants, with a 30-day over-allotment option for an additional 566,040 shares.
Gilead Sciences participated in the offering alongside other prominent healthcare investors, signaling confidence in the company's viral and liver disease pipeline.
• 5mo ago AI analysis › Press Release
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
Assembly Biosciences announced plans to expand the clinical development of its oral entry inhibitor ABI-6250 into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
The company plans to initiate a Phase 2 basket study in these cholestatic liver diseases in Q1 2027, following a constructive pre-IND meeting with the FDA.
This expansion builds on completed Phase 1a data showing target engagement and leverages the drug’s mechanism of inhibiting the NTCP receptor, which is central to bile acid transport.
• 5mo ago AI analysis › 
